JP7895177B2 - 大環状化合物とその使用 - Google Patents
大環状化合物とその使用Info
- Publication number
- JP7895177B2 JP7895177B2 JP2021554804A JP2021554804A JP7895177B2 JP 7895177 B2 JP7895177 B2 JP 7895177B2 JP 2021554804 A JP2021554804 A JP 2021554804A JP 2021554804 A JP2021554804 A JP 2021554804A JP 7895177 B2 JP7895177 B2 JP 7895177B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- methyl
- groups
- ring
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024102161A JP2024123202A (ja) | 2018-12-05 | 2024-06-25 | 大環状化合物とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018228234 | 2018-12-05 | ||
| JP2018228234 | 2018-12-05 | ||
| PCT/JP2019/048593 WO2020116660A1 (en) | 2018-12-05 | 2019-12-04 | Macrocyclic compound and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102161A Division JP2024123202A (ja) | 2018-12-05 | 2024-06-25 | 大環状化合物とその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510736A JP2022510736A (ja) | 2022-01-27 |
| JP2022510736A5 JP2022510736A5 (cg-RX-API-DMAC7.html) | 2022-11-30 |
| JP7895177B2 true JP7895177B2 (ja) | 2026-07-27 |
Family
ID=70975488
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554804A Active JP7895177B2 (ja) | 2018-12-05 | 2019-12-04 | 大環状化合物とその使用 |
| JP2024102161A Pending JP2024123202A (ja) | 2018-12-05 | 2024-06-25 | 大環状化合物とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102161A Pending JP2024123202A (ja) | 2018-12-05 | 2024-06-25 | 大環状化合物とその使用 |
Country Status (18)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210030A1 (ar) | 2018-08-20 | 2021-02-16 | Janssen Pharmaceutica Nv | مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2 |
| CN114174289B (zh) | 2019-05-31 | 2025-03-07 | Ube株式会社 | 苯并三唑衍生物 |
| BR112023004567A2 (pt) * | 2020-09-14 | 2023-04-04 | Sanofi Sa | Derivados de tetrahidroisoquinolina para o tratamento de doenças do sangue e doenças inflamatórias |
| AU2024251986A1 (en) * | 2023-04-03 | 2025-10-16 | Acelink Therapeutics, Inc. | Novel compounds and uses thereof |
| CN119707895B (zh) * | 2023-12-18 | 2026-03-31 | 江苏苏中药业研究院有限公司 | 一种7-甲酰基-2,3-二氢苯并呋喃-4-碳腈的制备方法 |
| WO2026026967A1 (zh) * | 2024-08-02 | 2026-02-05 | 劲方医药科技(上海)股份有限公司 | 丙烯酰基类化合物及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015092713A1 (en) | 2013-12-18 | 2015-06-25 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2018140876A1 (en) | 2017-01-30 | 2018-08-02 | Biogen Ma Inc. | Nrf2 activator |
| WO2018181345A1 (ja) | 2017-03-28 | 2018-10-04 | 武田薬品工業株式会社 | 複素環化合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103270022B (zh) | 2010-08-31 | 2015-08-19 | 巴勃罗·比咯斯拉达 | 神经营养蛋白受体激动剂及其作为药物的应用 |
| KR102322794B1 (ko) | 2013-06-21 | 2021-11-05 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 핵수송 조절인자 및 이의 용도 |
| LT3307739T (lt) | 2015-06-15 | 2021-03-10 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 reguliatoriai |
| KR20180017038A (ko) | 2015-06-15 | 2018-02-20 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| AU2016280236B2 (en) | 2015-06-15 | 2019-02-07 | Astex Therapeutics Limited | Nrf2 regulators |
| WO2017026516A1 (ja) | 2015-08-12 | 2017-02-16 | 持田製薬株式会社 | イソチアゾール誘導体 |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| US10351530B2 (en) | 2015-10-06 | 2019-07-16 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as NRF2 regulators |
| WO2018109641A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
| WO2018109642A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| ES2901617T3 (es) | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| EP3555068B1 (en) | 2016-12-14 | 2020-12-02 | GlaxoSmithKline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
| JP2020502123A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2アクチベーターとしてのビスアリール複素環 |
| JP2020502152A (ja) | 2016-12-15 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2アクチベーターとしてのエーテル結合トリアゾール |
| AU2017376900A1 (en) | 2016-12-15 | 2019-05-23 | Glaxosmithkline Intellectual Property Development Limited | NRF2 compounds |
| AR110590A1 (es) | 2016-12-27 | 2019-04-10 | Biogen Ma Inc | Activador de nrf2 |
| EP3573963B1 (en) | 2017-01-30 | 2021-09-01 | Biogen MA Inc. | Nrf2 activator |
-
2019
- 2019-12-04 UA UAA202102856A patent/UA127872C2/uk unknown
- 2019-12-04 KR KR1020217020790A patent/KR102919982B1/ko active Active
- 2019-12-04 BR BR112021010704-5A patent/BR112021010704A2/pt unknown
- 2019-12-04 AR ARP190103549A patent/AR117251A1/es unknown
- 2019-12-04 CN CN201980080214.5A patent/CN113164468A/zh active Pending
- 2019-12-04 US US17/299,659 patent/US11518763B2/en active Active
- 2019-12-04 CA CA3121952A patent/CA3121952C/en active Active
- 2019-12-04 NZ NZ776102A patent/NZ776102A/en unknown
- 2019-12-04 JP JP2021554804A patent/JP7895177B2/ja active Active
- 2019-12-04 TW TW108144324A patent/TWI820266B/zh active
- 2019-12-04 MX MX2021006527A patent/MX2021006527A/es unknown
- 2019-12-04 WO PCT/JP2019/048593 patent/WO2020116660A1/en not_active Ceased
- 2019-12-04 EP EP19892751.9A patent/EP3890738A4/en active Pending
- 2019-12-04 AU AU2019391942A patent/AU2019391942B2/en active Active
- 2019-12-04 SG SG11202105125XA patent/SG11202105125XA/en unknown
-
2021
- 2021-05-31 PH PH12021551262A patent/PH12021551262A1/en unknown
- 2021-06-02 CL CL2021001451A patent/CL2021001451A1/es unknown
- 2021-06-03 CO CONC2021/0007304A patent/CO2021007304A2/es unknown
-
2024
- 2024-06-25 JP JP2024102161A patent/JP2024123202A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015092713A1 (en) | 2013-12-18 | 2015-06-25 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2018140876A1 (en) | 2017-01-30 | 2018-08-02 | Biogen Ma Inc. | Nrf2 activator |
| WO2018181345A1 (ja) | 2017-03-28 | 2018-10-04 | 武田薬品工業株式会社 | 複素環化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021006527A (es) | 2021-07-21 |
| TWI820266B (zh) | 2023-11-01 |
| UA127872C2 (uk) | 2024-01-31 |
| KR20210099622A (ko) | 2021-08-12 |
| EP3890738A1 (en) | 2021-10-13 |
| WO2020116660A1 (en) | 2020-06-11 |
| SG11202105125XA (en) | 2021-06-29 |
| CA3121952A1 (en) | 2020-06-11 |
| CO2021007304A2 (es) | 2021-06-21 |
| AR117251A1 (es) | 2021-07-21 |
| US11518763B2 (en) | 2022-12-06 |
| JP2024123202A (ja) | 2024-09-10 |
| EP3890738A4 (en) | 2022-08-17 |
| CN113164468A (zh) | 2021-07-23 |
| TW202039494A (zh) | 2020-11-01 |
| BR112021010704A2 (pt) | 2021-08-24 |
| CL2021001451A1 (es) | 2021-12-24 |
| PH12021551262A1 (en) | 2021-10-25 |
| US20220119391A1 (en) | 2022-04-21 |
| AU2019391942B2 (en) | 2024-03-21 |
| KR102919982B1 (ko) | 2026-02-02 |
| AU2019391942A1 (en) | 2021-06-03 |
| CA3121952C (en) | 2025-05-13 |
| JP2022510736A (ja) | 2022-01-27 |
| NZ776102A (en) | 2024-12-20 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221121 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231226 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240507 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260714 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7895177 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |